Amgen AMGN

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. BRIEF- Amgen says blincyto leukemia drug to cost $178,000

      Headlines

      Wed, 17 Dec 2014

      Dec 17 (Reuters) - Amgen Inc : * Says blincyto leukemia drug to cost $178,000

    2. Ultimate Stock-Pickers: Top Holdings of Top-Performing Managers

      Headlines

      Tue, 16 Dec 2014

      49 1.01 Medium 81,866 7.7 Amgen AMGN 4 Wide 164.53 0.92 Low 123 ..... Cap (USD Mil) % Stock Holdings Amgen AMGN 4 Wide 164.53 0.92 Low 123 ..... slight reduction of its stake in Amgen AMGN "> AMGN . The downside to this approach

    3. Novartis copy of Amgen biotech drug shows similar efficacy-study

      Headlines

      Mon, 8 Dec 2014

      ZURICH, Dec 8 (Reuters) - Novartis said its copycat version of Amgen 's Neupogen for patients with low white blood cell counts works as well as the original drug in a late-stage trial.

    4. Addition of Amgen drug boosts benefits in relapsed myeloma -study

      Headlines

      Sat, 6 Dec 2014

      Dec 6 (Reuters) - Significantly more patients with relapsed multiple myeloma responded to a three-drug regimen including Amgen Inc's Kyprolis than those who got the standard two-drug treatment, according to results from a late-stage trial.

    5. Sandoz loses bid to shield psoriasis drug

      Headlines

      Fri, 5 Dec 2014

      Dec 5 (Reuters) - The top U.S. patent appeals court has upheld the dismissal of a lawsuit brought by Sandoz Inc that sought to shield its planned version of Amgen Inc's psoriasis and arthritis drug Enbrel from patent lawsuits.

    6. UPDATE 1-U.S. FDA approves Amgen leukemia drug ahead of schedule

      Headlines

      Wed, 3 Dec 2014

      Dec 3 (Reuters) - U.S. health regulators on Wednesday approved an Amgen Inc drug that helps the immune system fight a rare type of leukemia, more than five months ahead of the expected decision date.

    7. U.S. FDA approves Amgen leukemia drug ahead of schedule

      Headlines

      Wed, 3 Dec 2014

      Dec 3 (Reuters) - U.S. health regulators on Wednesday approved an Amgen Inc drug that helps the immune system fight a rare type of leukemia, more than five months ahead of the expected decision date.

    8. Amgen scraps trials of drug for advanced stomach cancer

      Headlines

      Mon, 24 Nov 2014

      Nov 24 (Reuters) - Amgen Inc on Monday said it will scrap all trials of its experimental treatment rilotumumab in patients with advanced stomach cancer, after a safety monitoring board associated it with a higher incidence of deaths.

    9. SINGAPORE PRESS- Amgen opens S$200 mln plant in Singapore-Straits Times

      Headlines

      Thu, 20 Nov 2014

      American pharmaceutical giant Amgen officially opened a S$200 million ($154 million) biomanufacturing facility in Tuas on Thursday, the Straits Times reported.

    10. Amgen psoriasis drug tops J&J's Stelara in Phase III study

      Headlines

      Tue, 11 Nov 2014

      Nov 11 (Reuters) - Amgen Inc said on Tuesday that its experimental psoriasis drug, brodalumab, met all the goals of a late-stage study, clearing the rough skin patches associated with the disease more thoroughly than Johnson & Johnson's Stelara and a placebo.

    « Prev12345Next »
    Content Partners